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Abstract
Background: A 60-year-old African American female patient, with chronic HIV infection since 1999, presented with markers of acute he-
patities B virus (HBV) infection for the past 15 months. The patient was previously vaccinated for HBV. Immunoglobulin dysfunction was 
hypothesized, but electrophoresis yielded no conclusive result. Results: Investigation suggests that the patient is a non-responder: so-
meone who fails to sero-convert to standard vaccinations. This condition can be linked to B-cell dysfunction due to chronic HIV infection. 
Conclusion: It is suggested that non-responders may require a 6-dose regimen to achieve sero-conversion for vaccination. Prevention of 
co-infection should be the mainstay of treatment, which is achieved by vaccination. However, immune system dysfunction can lead to 
complications.
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Introduction
Human Immunodeficiency Virus (HIV) compromises the immu-
ne response by destroying cells paramount to the immune sys-
tem, CD4 T-cells, eventually leading to morbidity and mortality 
from super-imposed infections, which commonly include Pneu-
mocystis jiroveci, Cytomegalovirus and Toxoplasmosis. This 
makes prevention through vaccination and prophylaxis the 
cornerstone of HIV management. One such prophylaxis option 
is against the Hepatitis B virus (HBV). HIV-HBV co-infection is 
associated with dangerous consequences and as a result, pre-
vention and/or management is extremely important. Despite 
antiretroviral therapy, around 10% of HIV patients who deve-
lop a super-imposed HBV co-infection develop liver disease.1 
Patients with this type of co-infection are at increased risk of 
developing cirrhosis and fibrotic liver changes.2
HBV co-infection is common in many HIV infected patients at 
time of diagnosis, mainly due to the fact that both conditions 
are sexually and parentally transmitted viruses prevalent in 
people who engage in IV drug abuse and unsafe sexual prac-
tices.3 The use of highly active antiretroviral therapy (HAART) 
has led to increased survival, and subsequently increased pre-
valence of chronic viral hepatitis among people living with HIV.4 
It is estimated that the prevalence of chronic co-infection is 
8-11% in HIV patients.5–8 As a result, it is routine to vaccinate 
all HIV patients for HBV. The Center for Disease Control (CDC) 
recommends that all high-risk patients receiving adult vaccina-
tions, be given a 3-dose vaccine series at 0, 1, and 6 months 
intramuscularly.9 However, many co-infected patients fail to se-
roconvert with standard vaccine administration they are dee-
med non-responders. Since co-infection has been attributed to 
a 19-fold increase in mortality,10 it is important to establish a 
care plan for non-responders. This article discusses the clinical 
presentation of a non-responder and discusses the methods of 
management for such a patient.
The Case
A 60-year-old African American woman with chronic HIV infec-
tion presented to the clinic for a routine follow-up. She con-
tracted HIV in 1999, and started treatment 4 months after the 
diagnosis. On her previous visit in January 2012, she showed 
serological evidence of an acute HBV infection, but with no cli-
nical signs or symptoms. On that visit she was given treatment 
for HBV with raltegravir and HBV vaccine (Table 1). In April of 
2013 the patient’s blood tested positive for only HBc IgM anti-
body which was shown to be persistent for 15 months. Her CD4 
count at this time was 947. She still denied any symptoms such 
as weakness, fever, or right upper quadrant pain.
Her past medical history included a diagnosis of HIV in 1999, 
hypertension in 1994, depression in 2000, hyperlipidemia, la-
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          Key Points:
• HIV and HBV co-infection is a common occurrence amongst HIV patients. 
This co-infection increases morbidity and mortality, and calls for particu-
lar treatment solutions. 
• HIV patients can present with unique immune problems, such as B-cell 
dysfunction.
• Viral infections and B-cell dysfunction can decrease the effectiveness 
of standard vaccinations, therefore making patients non-responsive to 
standard vaccinations. 
• This articles discusses a case study of an HIV-HBV co-infected patient 
who presents as a possible non-responder to standard HBV vaccination.
• We have suggested methods to deal with patients who present as 
non-responders to standard HBV vaccinations.
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tent TB, HIV-related lipodystrophy syndrome, past history of 
gonorrhea, and an acute HBV infection. Her social history is 
significant for previous intravenous drug use she has been off 
drugs since the diagnosis of HIV. Her current anti-retroviral me-
dications are atazanavir (Reyataz), ritonavir (Norvir) and ralte-
gravir (Isentress). Medications to help control her hypertension 
are hydrochlorothiazide (HCTZ) and valsartan (Diovan). Finally, 
pravastatin (Pravachol) is used to control the hyperlipidemia. 
She has drug allergies to erythromycin and codeine.
On physical exam, the patient’s vital signs were found to be 
within normal limits – meaning her temperature was 98.0o F, 
pulse was 78, respirations were 16 and her blood pressure was 
110/70.  She was found to be moderately obese with a BMI of 
32.3 Kg/m2 given her height of 65 inches and weight of 194 
pounds.  She did not seem to be in any obvious distress and 
showed signs of being normotensive and non-cachectic.  Her 
head was normocephalic, pupils were equal and reactive, tym-
panic membranes were clear, mucosal surfaces were pink, and 
her throat was non-erythematous and free of exudates.  Upon 
auscultation, her lungs were clear bilaterally, heart sounds 
were regular and there were not any murmurs or gallops and 
normal bowel sounds were heard in all four abdominal qua-
drants.  Her abdomen was also soft, non-tender and there were 
not any signs of hepatosplenomegaly.
When the patient first presented in May 2012, her IgG and IgA 
were normal, and it was only her IgM that was subpar (1372, 
246 and 31, respectively).  A complete blood count (CBC) was 
drawn 4 months later (September 2012) and revealed a WBC of 
5.5, hemoglobin (Hgb) 12.9, hematocrit (Hct) 38 and platelets 
were 192,000. During the same visit, a lipid panel was ordered 
and the results showed a total cholesterol of 254, low-density 
lipoprotein (LDL) of 17, triglycerides (TG) of 159 and high-den-
sity lipoproteins (HDL) of 52. Given her total cholesterol levels, 
the need to prescribe pravastatin was clear.
Discussion
This patient has a chronic HIV infection and presents with signs 
atypical of an acute HBV infection. Although numerous past 
attempts had been made to vaccinate this patient, she later 
presented with HBV after originally testing was negative. This 
patient classifies as a non-responder, due to failure to serocon-
vert, and produce IgG HBV surface antibodies.  She has elevated 
levels of IgM core antibody, which typically presents during 
an acute infection. Furthermore, she has failed to produce IgG 
core antibodies or surface antibodies after 15 months of in-
fection (Table 1). Thirty percent of viral hepatitis patients with 
associated drug use may present with isolated anti-HBc. These 
individuals tend to have a varied response to vaccination.11 It 
has been suggested that such patients may present with an 
occult liver disease.11 It was originally hypothesized that this 
particular patient may have had an IgG immunoglobulin defi-
ciency. However, electrophoresis revealed the patient has IgG 
immunoglobulin the laboratory reference range. 
Regardless of a typical or atypical presentation of HBV-HIV 
co-infection, a management plan is necessary. A review of lite-
rature has allowed advisement on suggested protocols to mo-
nitor and treat such patients.
Typically CD4 counts and HIV viral loads are used to monitor 
the disease process; however, B-Cells can also be affected in 
HIV.6 HIV can affect and cause abnormalities in any lymphocyte 
group. Specifically, HIV can affect the frequency and composi-
tion of B-Cell subsets, especially in patients with chronic infec-
tion.12 The B-Cell dysfunction usually manifests as a decreased 
responsiveness to antigens, despite hypergammaglobulinemia 
and hyperactivity of the B-cells.13 
In a 2012 study, vaccine responders and non-responders were 
followed after the diagnosis of HIV and subsequent vaccination. 
The goal of the study was to determine if non-responders were 
at an increased risk of mortality. It was concluded that hepatitis 
B surface antibodies could assist in the prediction of the pro-
gression to AIDS from HIV-infected patients.6 It was discovered 
that non-responders were associated with a 2-fold increase in 
AIDS and/or death. It is hypothesized that HIV may play a role 
in the dysfunction of the interaction between the ligand of CD4 
T-cells and B-Cells.6 
HBV vaccination in HIV patients should be done while CD4 cell 
Vaccine/Test Results [Date]
  Hepatitis Vaccine [09/1999, 11/1999, 02/2000, 04/2012]
  Pneumovax [2009]
  Fluvax [10/2011]
  RPR Negative [6/2011]
  Viral Load: HIV-1 < 75 undetectable [01/2012], [5/25/2012]
  HCV sAb titer Negative date: [4/24/2013]
  Hepatitis screen HBc IgM(+) Ab, HBsAg(-), HBsAb(-), HCV (-)[5/25/2012], [4/24/2013]
  CD4 count 796 [01/2012], 880 [5/25/2012], 947 [4/24/2013]
  CBC WBC 5.5, HGB 12.9, HCT 38, platelets 192,000 [9/29/2012]
  Lipids Chol 254, LDL 17, TG 159, HDL 52 [9/29/2012]
  Immunoglobulin G 1372 mg/dl (ref range 694 - 1618) [5/25/2012]
  Immunoglobulin A 246 mg/dl (ref range 81 - 463) [5/25/2012]
  Immunoglobulin M 31 mg/dl (ref range 48 - 271) [5/25/2012]
Labels: Pneumovax = pneumococcal vaccine, Fluvax = influenza vaccine, RPR = rapid plasma reagin for syphilis testing, HIV-1 = human immunodeficiency virus type 1, HCV sAb = 
hepatitis C vaccine serum antibody, HBc IgM Ab = hepatitis B core immunoglobulin M antibody, HBsAg = hepatitis B surface antigen, HBsAb = hepatitis B surface antibody, CD4 = cluster 
of differentiation 4, CBC = complete blood count, WBC = white blood cells, HGB = hemoglobin, HCT = hematocrit, Chol = cholesterol, LDL = low-density lipoprotein, TG = triglycerides, 
HDL = high-density lipoprotein.
Table 1. HIV Patient Labs Showing Resistance to Hepatitis B Vaccine Series.
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count is above 200, to achieve a higher probability of success-
ful vaccination. Alternatively, patients who have a CD4 count 
below 200, should receive HAART first and then vaccinate when 
CD4 count is above 200.7 Our patient has failed to seroconvert 
while having a CD4 count in the optimal range (Table 1).
Increased standard doses of hepatitis B virus vaccine, may 
prove to increase the results of seroconversion of non-respon-
ders.3 The current standard dose is three 20μM of vaccine given 
at 0, 1, and 6 months.9  In a study of 20 patients, it was disco-
vered that non-responders receiving 6 doses had a seroconver-
sion rate of >90%. The doses were given at 0, 1, and 2 months, 
followed by 3 additional doses at 3, 4, and 5 months.3
Co-infection of HBV and HIV requires special treatment. Co-in-
fection can be treated with tenofovir.4 Lamivudine, has been 
used to treat these types of infections however, there are some 
infections that show resistance to lamivudine, thus allowing 
tenofovir to be used as an effective agent. The goal of therapy 
is to have a patient who is HIV-seronegative, with a mana-
geable chronic hepatitis B state. Management should include 
monitoring liver histology, and prolongation of the time to de-
velopment of end-stage liver disease.14
The most important management step of a HIV-HBV co-infec-
tion is prevention. Therefore, obtaining seroconversion should 
be the primary goal of medical treatment. Patients with a CD4 
count below 200, should be treated with HAART in an effort to 
increase the CD4 count above 200 and increase the chances of 
seroconversion. In a patient with increased co-infection risk 
factors, such as continued intravenous drug use, utilization of 
a 6-doses vaccination method may be warranted. Alternatively, 
this method could also be used after failure of the standard 
vaccination regimen. The current literature emphasizes the im-
portance of preventing co-infection. Furthermore, if a patient 
does develop co-infection, treatment with tenofovir should be 
administered as it has been shown to have a decreased rate 
of resistance.
Co-infection with HIV and HBV has an increased risk of mor-
bidity and mortality. Prevention of co-infection should be 
the mainstay of treatment, which is achieved by vaccination. 
However, immune system dysfunction can lead to complica-
tions with vaccination, and result in vaccination non-respon-
ders. By knowing that B-cell dysfunction can lead to vaccine 
failure, a physician can better understand why alternative vac-
cine dosing regimens may be appropriate. In situations where 
co-infection is already present, treatment with an antiretroviral 
such as tenofovir should be used. The ultimate goal of mana-
gement is to decrease viral serology, achieve a state where 
HIV viral load is undetectable, and delay the progression of 
end-stage liver disease.
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